Every vial of Botox Cosmetic that enters an aesthetic practice carries a lot number, an expiration date, and a National Drug Code. From the moment it arrives to the moment the last unit is injected or discarded, the practice is responsible for maintaining a traceable chain. A recall, an adverse event report, or a board audit will ask one question first: which lot went into which patient, on which date, administered by whom?
This article covers the vial log workflow for botulinum toxin in an aesthetic practice — from receipt through reconstitution, storage, patient treatment, and wastage documentation.
The Regulatory Foundation
Botox Cosmetic (onabotulinumtoxinA) is manufactured by Allergan Aesthetics, an AbbVie company. The FDA-approved prescribing information specifies that unreconstituted vials should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Before reconstitution, the product is a vacuum-dried powder supplied in 50-Unit and 100-Unit single-dose vials.
The label states: "Record the date and time of reconstitution on the space on the label. Administer BOTOX Cosmetic within 24 hours after reconstitution. During this time period, store reconstituted BOTOX Cosmetic in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze reconstituted BOTOX Cosmetic. BOTOX Cosmetic vials are for single-dose only. Discard any remaining solution."
The phrase "single-dose only" in the FDA label creates a tension with clinical reality: most aesthetic practices reconstitute a 100-unit vial and use it across multiple patients in the same session or the same day, because discarding 60 unused units after treating one patient is economically unsustainable.
The American Society for Dermatologic Surgery addressed this directly. In a 2015 consensus statement reaffirmed in 2024, the ASDS task force concluded by unanimous consensus that a vial of botulinum toxin A, reconstituted in a clinically appropriate manner, can be used to treat multiple patients, assuming appropriate handling. The task force further concluded that reconstituted vials can be refrigerated for at least four weeks without clinically significant risk of contamination or decreased effectiveness.
This creates a two-layer compliance framework:
- FDA label: single-dose, 24-hour storage window.
- ASDS consensus (clinical standard of care): multi-patient use acceptable with proper handling; refrigerated storage for at least four weeks.
Practices that follow the ASDS consensus should document that they are doing so explicitly — not silently deviate from the label. The vial log is where that documentation lives.
Vial Receipt and Intake Logging
When a shipment of botulinum toxin arrives:
Verify authenticity. Allergan Aesthetics reports that counterfeit Botox has entered the U.S. market. Authentic Botox Cosmetic has a tamper-evident seal on the carton, the established name "onabotulinumtoxinA" listed under the brand name, and a hologram of the word "Allergan" on the vial label. The U.S. License number 1889 appears on the vial label and carton. If any of these features are absent or appear compromised, do not use the product and contact AbbVie at 1-800-678-1605.
Record receipt. Log each vial with:
- Product name and formulation (Botox Cosmetic 100-Unit, Dysport 300-Unit, Xeomin 50-Unit, etc.).
- Lot/batch number.
- Expiration date.
- NDC (National Drug Code).
- Date received.
- Supplier/distributor name.
- Condition on arrival (cold pack intact, packaging undamaged).
Storage immediately. Place unreconstituted vials in the designated refrigerator at 2°C to 8°C. Xeomin (incobotulinumtoxinA) is the exception — it does not require refrigeration before reconstitution, per its prescribing information from Merz Pharmaceuticals.
Assign internal tracking. Many practices assign an internal lot number or use the manufacturer lot number to track each vial through its lifecycle in the practice.
Reconstitution Documentation
Reconstitution is the point where the vial transitions from inventory to patient-ready medication. The reconstitution log should capture:
- Date and time of reconstitution. The Botox Cosmetic label includes a space on the vial label specifically for this. Record it on the vial itself and in the log.
- Diluent used. The FDA label specifies preservative-free 0.9% sodium chloride injection. The ASDS consensus notes that preserved saline is routinely used, has been shown to reduce patient discomfort, and is not associated with adverse events. Whatever diluent is used, document it.
- Volume of diluent. For a 100-unit vial of Botox Cosmetic, the on-label reconstitution is 2.5 mL, yielding 4 units per 0.1 mL. Document the exact volume used.
- Resulting concentration. Calculate and record the units per 0.1 mL.
- Who reconstituted. Any trained team member may reconstitute, but the identity should be recorded.
- Vial lot number. Carry the lot number forward from intake to reconstitution to patient treatment.
The Patient Treatment Link
Every patient treated from a reconstituted vial must have the following recorded in their chart:
- Product name and lot number.
- Date and time of injection.
- Injection sites and units per site.
- Total units administered from the vial.
- Units discarded (if any).
- Name of the injecting provider.
The lot-number-to-patient link is the reason the log exists. In a recall scenario, the practice must be able to identify every patient who received product from a specific lot within hours, not days. The American Academy of Ophthalmology reinforces this standard: "For all buy-and-bill drugs, have a system in place for tracking the purchase and use of each vial. Record the patient name, date of service, lot number, and expiration date."
This can be managed in an EMR with integrated inventory tracking (platforms like Aesthetic Record offer lot-number reports that link patients to specific batches), or in a manual spreadsheet. The method matters less than the consistency.
Storage Compliance: Temperature and Time
Temperature monitoring is a compliance requirement that many aesthetic practices handle informally. A defensible storage protocol includes:
- Designated medication refrigerator. Not a staff-break-room fridge. Not a mini-fridge that gets unplugged over the weekend. A dedicated unit maintained at 2°C to 8°C with a documented temperature monitoring log.
- Temperature log. Recorded at least daily (ideally twice daily) with the date, time, temperature, and initials of the person checking. Digital temperature monitors with data logging are preferable to manual checks.
- Excursion protocol. What happens when the temperature is recorded outside range? The protocol should define the acceptable excursion window, who to notify, and when to discard affected vials.
- Reconstituted vial storage. Per the ASDS consensus, reconstituted botulinum toxin may be stored refrigerated for at least four weeks. The practice must decide whether to follow the FDA label (24 hours) or the ASDS consensus (four weeks) and document that decision in its standard operating procedures. If following the consensus, the reconstitution date on each vial must be clearly visible, and vials past the practice's designated storage window must be discarded with documentation.
Wastage Tracking
Units of botulinum toxin that are drawn into a syringe but not injected are wastage. The FDA label for Botox Cosmetic states that vials are single-dose and any remaining solution should be discarded. Under the ASDS consensus, multi-patient use is acceptable — but wastage still must be documented.
Wastage tracking serves three purposes:
Audit trail. If a practice purchases 100 vials per month and treats 300 patients at an average of 40 units each, the math should reconcile. Large unexplained discrepancies between purchase volume, patient treatments, and documented wastage raise questions about diversion or unauthorized use.
Economic optimization. Tracking wastage by provider and by day of week helps practices schedule patients to maximize vial utilization. A practice that consistently wastes 20–30 units per vial can reduce that loss by scheduling toxin patients sequentially rather than scattering them across the day.
Recall and adverse-event linkage. If a patient reports an adverse event and the practice needs to identify everyone treated from the same lot, the wastage record confirms that no additional patients received product from that vial.
Document wastage as: vial lot number, units drawn, units injected, units discarded, provider name, date, and reason for discard (end of session, expiration, patient cancellation, visual particulate detected).
The Complete Audit Trail
A board investigator, a malpractice attorney, or a practice auditor who asks to see the botulinum toxin management system should be able to trace any of these paths:
- Forward trace (lot to patient): Given a lot number, produce a list of every patient who received product from that lot, with dates and providers.
- Backward trace (patient to lot): Given a patient name and treatment date, produce the lot number, expiration date, reconstitution date, and provider who treated them.
- Inventory reconciliation: Given a purchase period, show that the number of vials purchased equals the number of patients treated (multiplied by average units used) plus documented wastage plus current inventory.
If any of these traces produces a gap, the audit trail has a hole that a board complaint will exploit.
Sources
- Botox Cosmetic (onabotulinumtoxinA) Prescribing Information, AbbVie/Allergan Aesthetics: https://www.rxabbvie.com/pdf/botox-cosmetic_pi.pdf
- Botox Cosmetic Reconstitution Guide: https://www.botoxcosmetichcp.com/content/dam/botox-cosmetic-hcp/documents/BTXC%20How-To%20Reconstitute%20Guide.pdf
- American Society for Dermatologic Surgery, "Consensus Statement Regarding Storage and Reuse of Previously Reconstituted Neuromodulators" (2015, reaffirmed 2024): https://www.asds.net/Portals/0/PDF/asdsa/white-paper-storage-and-reuse-of-reconstituted-neuromodulators.pdf
- ASDSA Position Statement on Storage and Reuse of Botulinum Toxin A: https://www.asds.net/Portals/0/PDF/asdsa/asdsa-position-statement-storage-and-reuse-of-botulinum-toxin-a.pdf
- Allergan Aesthetics, "Response to Suspected Counterfeit Botox Reports": https://news.allerganaesthetics.com/media/response-to-suspected-counterfeit-botox-reports
- American Academy of Ophthalmology, "Functional Botox Treatments — Quick Tips for Documentation and Coding": https://www.aao.org/eyenet/article/functional-botox-treatments-documentation-coding
- CDC, "Preventing Unsafe Injection Practices": https://www.cdc.gov/injection-safety/hcp/clinical-safety/index.html
- FDA, Botox Prescribing Information (accessdata.fda.gov): https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103000s5318lbl.pdf
